Vivax malaria: a possible stumbling block for malaria elimination in Indiaarticle Published on 2024-01-312024-09-01 Journal: Frontiers in public health [Category] 말라리아, [키워드] Elimination glucose-6-phosphate dehydrogenase Hypnozoites Plasmodium vivax primaquine Relapse Vaccine [Article Type] article
Vivax malaria: a possible stumbling block for malaria elimination in IndiaPublic Health Review Published on 2024-01-082024-09-05 Journal: Frontiers in public health [Category] update2024, [키워드] Elimination glucose-6-phosphate dehydrogenase Hypnozoites Plasmodium vivax primaquine Relapse Vaccine [DOI] 10.3389/fpubh.2023.1228217 PMC 바로가기 [Article Type] Public Health Review
Genetic basis and spatial distribution of glucose-6-phosphate dehydrogenase deficiency in ecuadorian ethnic groups: a malaria perspective에콰도르 민족 집단에서 포도당-6-인산 탈수소효소 결핍의 유전적 기초와 공간적 분포: 말라리아 관점Article Published on 2023-09-262024-08-01 Journal: Malaria Journal [Category] 말라리아, [키워드] Afro-Ecuadorians Ecuador G6PD deficiency glucose-6-phosphate dehydrogenase Malaria clusters pharmacogenetics single nucleotide variants [DOI] 10.1186/s12936-023-04716-x PMC 바로가기
The Possible Role of Glucose-6-Phosphate Dehydrogenase in the SARS-CoV-2 InfectionArticle Published on 2022-06-212023-07-09 Journal: Cells [Category] COVID19(2023년), [키워드] COVID-19 glucose-6-phosphate dehydrogenase pentose phosphate pathway redox homeostasis. SARS-CoV-2 Warburg effect [DOI] 10.3390/cells11131982 PMC 바로가기
G6PD distribution in sub-Saharan Africa and potential risks of using chloroquine/hydroxychloroquine based treatments for COVID-19사하라 사막 이남 아프리카의 G6PD 분포 및 COVID-19에 대한 클로로퀸/하이드록시클로로퀸 기반 치료제 사용의 잠재적 위험Article Published on 2021-07-232022-09-10 Journal: The Pharmacogenomics Journal [Category] 변종, 유전자 메커니즘, 임상, 진단, [키워드] African allele frequency Analysis Chloroquine chloroquine/hydroxychloroquine clinical trial clinical trials continent country COVID-19 deficiency Deleterious distribution drug G6PD Genetics research Genotype Glucose Glucose-6-phosphate glucose-6-phosphate dehydrogenase Hydroxychloroquine individual nine potential risk Potential treatment potential treatments Predictive medicine Prevalence significant difference significant differences significant interaction South Africa sub-Saharan Africa Treatment treatments for COVID-19 variant variants Variation whole genome sequence [DOI] 10.1038/s41397-021-00242-8 PMC 바로가기 [Article Type] Article
Glucose-6-phosphate dehydrogenase inhibitor for treatment of severe COVID-19: Polydatin중증 코로나19 치료를 위한 포도당-6-인산 탈수소효소 억제제: 폴리다틴Article Published on 2021-06-012022-08-31 Journal: Clinical nutrition ESPEN [Category] MERS, SARS, 치료법, 치료제, [키워드] Activation acute pulmonary injury Anti-inflammatory antioxidant antioxidants approach balance best biological activity can be used complementary Consumption COVID 19 COVID-19 COVID-19 pandemic COVID-19 patients effective Emergency FDA-approved drug G6PD global public health glucose-6-phosphate dehydrogenase glucoside Health crisis Health Organization Hypothesis Infection Inflammation inhibiting inhibitor mechanisms oxidative oxidative stress pandemic Patient patients with COVID-19 peanuts plant Polydatin Polydatin. Polygonum progression protein-protein interaction reducing respond resveratrol SARS-COV-2 infection Stress switching Therapeutic approach therapy tissue injury treat Treatment Tumor urgency WHO World Health Organization [DOI] 10.1016/j.clnesp.2021.02.021 PMC 바로가기 [Article Type] Article
Glucose-6-Phosphate Dehydrogenase Deficiency-Associated Hemolytic Anemia and Methemoglobinemia in a Patient Treated With Hydroxychloroquine in the Era of COVID-19Internal Medicine Published on 2021-05-252022-10-31 Journal: Cureus [Category] COVID-19, [키워드] acute respiratory syndrome coronavirus COVID-19 COVID-19 pandemic Critical deficiency dehydrogenase Diagnosis disease disorder Effect G6PD Genetic variant glucose-6-phosphate dehydrogenase glucose-6-phosphate dehydrogenase (g6pd) hemolytic hemolytic anemia Hydroxychloroquine individual Infection knowledge management methemoglobinemia oxidative Patient patients physician Prevalence recognize red blood cell Region SARS-CoV-2 severity subset unique [DOI] 10.7759/cureus.15232 PMC 바로가기 [Article Type] Internal Medicine
Therapeutic Intervention of COVID-19 by Natural Products: A Population-Specific Survey Directed Approach천연물에 의한 COVID-19의 치료적 개입: 특정 인구 조사 지향 접근법Review Published on 2021-02-232022-09-10 Journal: Molecules [Category] MERS, 진단, 치료제, [키워드] activity addition Antiviral approach can be used Cell Community Comorbidity Compound COVID-19 Critical cytokine Cytokine storm deficiency Disparities docking study Effect enzymopathy Factor focus G6PD Genetic genetic factors Genome Glucose Glucose-6-phosphate glucose-6-phosphate dehydrogenase glucose-6-phosphate dehydrogenase deficiency Health host response immune responses immunomodulatory property IMPROVE in vitro in-silico in-silico docking include independent independent of individual innate immune responses Intervention lead leads life style variables management molecular natural natural product outcomes Prevalence protein targets rationale review risk factor Risk factors SARS-CoV-2 SARS-COV-2 infection Secondary Metabolite secondary metabolites selected survey targets the cytokine storm therapeutic intervention therapeutic interventions Treatment variable Viral viral infection virulence [DOI] 10.3390/molecules26041191 PMC 바로가기 [Article Type] Review
Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience인간 백혈구 항원 복합체 및 기타 면역유전학적 및 임상적 요인은 SARS-CoV-2 감염에 대한 감수성 또는 보호 및 질병 경과의 중증도에 영향을 미칩니다. 사르데냐 체험Randomized Controlled Trial Published on 2020-12-042022-08-13 Journal: Frontiers in Immunology [Category] MERS, SARS, 유전자 메커니즘, 임상, 진단, [키워드] 95% CI All participants allele alleles analyzed Asymptomatic asymptomatic or pauci-symptomatic patients Autoimmune disease Autoimmune diseases beta-thalassemia beta-thalassemia trait beta-thalassemic trait Care carried clinical Clinical data Clinical outcome clinical, genetic and immunogenetic factors collected controls Course COVID-19 severity deficiency Demographic and clinical data disease course DRB1 evaluate experience extended haplotype Factor Frequency G6PDH G6PDH deficiency Genetic genetic factor genetic factors Genetic polymorphism Glucose Glucose-6-phosphate glucose-6-phosphate dehydrogenase haplotype frequencies haplotypes health problem healthy HLA allele HLA class I HLA class I and II molecules HLA-A HLA-A*02:05, B*58:01, C*07:01 HLA-A*30:02 HLA-A*30:02, B*14:02, C*08:02 HLA-C HLA-C*04:01 allele HLA-DRB1*08:01 allele home care home care patients hospital hospital care hospitalized patient hospitalized patients Human human leukocyte antigen immunogenetic background immunogenetic factors in-patient infections influence Influenza influenza vaccination Italy Male sex material Mild disease negative influence Older age Other Participants Pathogenesis Patient patients pauci-symptomatic phosphate predisposing factor protection protective effect public health recruited related clinical consequence related clinical consequences required Result Sardinia Sardinian Sardinian control Sardinian population SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 patients seasonal flu severe disease Sex susceptibility Taking thalassemia the disease three-loci haplotype vaccination with mild disease without symptoms world-wide public health problem [DOI] 10.3389/fimmu.2020.605688 PMC 바로가기 [Article Type] Randomized Controlled Trial
Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial)증상이 있는 SARS-CoV-2 감염(COVID-19)이 있는 고령자의 가정 치료: 여러 가지 실험적 치료의 효능과 내약성을 평가하기 위한 MAMS(Multi-Arm Multi-Stage) 무작위 시험에 대한 연구 프로토콜의 구조화된 요약 65세 이상 외래 환자의 입원 또는 사망 위험 감소(COVERAGE 시험)Letter Published on 2020-10-132022-08-13 Journal: Trials [Category] MERS, SARS, 임상, [키워드] 6-mercaptopurine Abnormalities ACEi added age amodiaquine Analysis antrafenine approved ARB ARBs Arm azathioprine Blinding Bordeaux Caregivers Chloroquine chronic hepatitis Chronic kidney disease citalopram clinical Colitis Combination comparator complex conducted Control control arm COVID-19 COVID-19 pandemic criteria CYP3A4 cytochrome P450 Dasatinib death Dementia dialysis dissemination Domperidone drug Duchy Efficacy element enrolled enrolment Enterocolitis escitalopram EudraCT Evidence exclusion criteria experimental arm experimental drug Experimental drugs Favipiravir feasibility Final final analysis first symptom first symptoms floctafenine France French futility galactose GFR glafenine Glucose Glucose-6-phosphate glucose-6-phosphate dehydrogenase glucose-6-phosphate dehydrogenase deficiency Grand duchy halofantrine Health Insurance heart rate hepatic Hepatic porphyria home hospital hospitalisation Hydroxychloroquine hydroxyzine hypersensitivity Hyperuricemia Ileus Imatinib immunological incidence Inclusion increase in inducer inhibitor Interim analyses interim analysis intervals investigator investigators Isoenzyme Kidney disease Lactase Lactose liver failure Long Long QT syndrome Luxembourg malabsorption mefloquine mercaptopurine metabolism multi multi-arm nasopharyngeal Nasopharyngeal swab New Nilotinib not blinded number nursing home nursing homes objective Older Open-label open-label trial other treatment other treatments outcome Outpatient P450 Paris participant Patient performed phase Piperaquine Positive test Prevent primary care Primary outcome proportion protocol pyrazinamide QTc interval randomisation randomised Randomized Randomly receive recruited Region Registered regulatory authority repaglinide replaced REPLACED BY reported Repurposed drug residence Safety Monitoring Board Sample size SARS-CoV-2 SARS-COV-2 infection scale Stage Standard statistician statisticians status stratified Study protocol submitted symptomatic SARS-CoV-2 infection Tablet telmisartan tested theophylline Toxicity Trace element trace elements treated Treatment treatment arm Trial Trial registration Version virus Virus Disease Vitamin vitamins Warfarin [DOI] 10.1186/s13063-020-04619-1 PMC 바로가기 [Article Type] Letter